MDGL

Madrigal Pharmaceuticals Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↑ 6/10
  • Value↑ 6/10
Madrigal Pharmaceuticals sales and earnings growth
MDGL Growth
Good
  • Revenue Y/Y↑ 243.45%
  • EPS Y/Y↑ 25.90%
  • FCF Y/Y↑ 31.39%
Madrigal Pharmaceuticals gross and profit margin trends
MDGL Profitability
Neutral
  • Gross margin ↑ 93.10%
  • EPS margin↓ -27.30%
  • ROIC 5Y↓ -100.16%
Madrigal Pharmaceuticals net debt vs free cash flow
MDGL Risk
Great
  • Debt / Equity↓ 0.6
  • Debt / FCF↓ 0.4
  • Interest coverage↓ -10.5

Madrigal Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks